

CURRICULUM VITAE**INFORMAZIONI PERSONALI**

Nome	Veronica Redaelli
Data di nascita	12/11/1981
Qualifica	Dirigente medico neurologo
Amministrazione	ISTITUTO NEUROLOGICO C. BESTA - MILANO
Incarico attuale	Dirigente medico presso il reparto di Neurologia 2
Numero telefonico dell'ufficio	0223942240
Fax dell'ufficio	
E-mail istituzionale	veronica.redaelli@istituto-besta.it

TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE

Titolo di studio	Specializzazione in Neurologia, Laure in Medicina e Chirurgia		
Altri titoli di studio e professionali	Laurea magistrale in biotecnologie mediche		
Esperienze professionali (incarichi ricoperti)	Neurologo con rapporto di co.co.co. presso l'istituto Neurologico Besta da luglio 2017 a novembre 2020. Esperienza in laboratorio di Neuropatologia Esperienza in laboratorio di biologia molecolare Docente corso di neuroanatomia presso ICOM International school of osteopathy		
Capacità linguistiche	Lingua	Livello Parlato	Livello Scritto
	[Inglese]	fluente	fluente
Capacità nell'uso delle tecnologie	Buona		
Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazioni a riviste, ecc. e ogni altra informazione che il dirigente ritiene di dover pubblicare)	• Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Giaccone G et al Acta Neuropathol. 2010 Dec;120(6):803-12. • A novel progranulin mutation causing frontotemporal lobar degeneration with heterogeneous phenotypic expression. Rossi G et al, J Alzheimers Dis. 2011 Jan 1;23(1):7-12. • Stereotypic behaviors in degenerative dementias. Prioni S et al. J Neurol. 2012 Nov;259(11):2452-9. • A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. JAMA Neurol. 2013 Jan;70(1):25-33. • Panencephalopathic Creutzfeldt-Jakob disease with distinct		

CURRICULUM VITAE

	pattern of prion protein deposition in a patient with D178N mutation and homozygosity for valine at codon 129 of the prion protein Gene. Marcon G, et al Brain Pathol. 2014 Mar;24(2):148-51. • Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Haik S, et al, Lancet Neurol. 2014 Feb;13(2):150-8.. • Normal pressure hydrocephalus and parkinsonism: the essential teamwork between the neurosurgeon and the neurologist. Broggi M, et al. World Neurosurg. 2014 Dec;82(6) • Mathematical models for the diffusion magnetic resonance signal abnormality in patients with prion diseases. Figini M, et al. Neuroimage Clin. 2014 Nov 29;7:142-54. • Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Forloni G,et al.. Prion. 2015;9(2):75-9. • Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Karch CM, et al.Neurobiol Aging. 2016 Feb;38:215 • Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Bocchetta M, et al.; SINDem. J Alzheimers Dis. 2016 Jan 29;51:277-91 • Normal Pressure Hydrocephalus and Parkinsonism: Preliminary Data on Neurosurgical and Neurological Treatment. Broggi M, et al. World Neurosurg. 2016 Jun;90:348-56. • Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (TAR DNA-binding protein 43 inclusions) in missense progranulin mutation Cys139Arg. Redaelli V, et al. Brain Pathol. 2016 Dec 20. • Detection of prion seeding activity in the olfactory mucosa of patients with Fatal Familial Insomnia. Redaelli V, et al. Sci Rep. 2017 Apr 7;7:46269. • Clinical features, pathophysiology and management of fatal familial insomnia. Redaelli V, et al.F. Expert opinion on orphan drugs, Volume 5, Issue 5, 17 Apr 2017. • Towards an early clinical diagnosis of sporadic CJD VV2 (ataxic type). Baiardi S,et al.. J Neurol Neurosurg Psychiatry. 2017 Jul 1. pii: jnnp-2017-315942. doi: 10.1136/jnnp-2017-315942 • Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges Samir Abu-Rumeileh, et al. ANN NEUROL 2018;84:347–360 • Stereotypic behaviours in frontotemporal dementia and progressive supranuclear palsy. Sara Prioni, et al. Cortex 109 (2018) 272 e 278 • Frontotemporal Dementia and Chorea Associated with a Compound Heterozygous TREM2 Mutation. Veronica Redaelli,et al.. Journal of Alzheimer's Disease 63 (2018) 195–201
--	---

CURRICULUM VITAE

- | | |
|--|--|
| | <ul style="list-style-type: none">• Tau mutations serve as a novel risk factor for cancer. Giacomina Rossi, et al. Cancer Res. 2018 July 01; 78(13): 3731–3739• Tau Mutations as a Novel Risk Factor for Cancer—Response. Giacomina Rossi, et al.. Cancer research October 29, 2018; DOI: 10.1158/0008-5472.CAN-18-2730• Prion-related peripheral neuropathy in sporadic Creutzfeldt-Jakob disease. Simone Baiardi, et al.J Neurol Neurosurg Psychiatry 2019;90:424–427.• A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). Leire Palencia-Madrid, et al.Neurobiology of Aging 84 (2019) 236.e9e236.e15• Publications of The Genetic Frontotemporal Dementia Initiative (GENFI). |
|--|--|